Artelo Biosciences Soars 6.84% on Promising Depression Drug Data

Artelo Biosciences' stock surged 6.84% in pre-market trading on July 8, 2025, driven by positive preclinical data for its drug candidate ART12.11 in a stress-induced depression model.

Artelo Biosciences reported that ART12.11 significantly restored key depression-related behaviors to baseline levels in a stressed rodent model. The drug demonstrated efficacy comparable to Pfizer's antidepressant Zoloft, indicating its potential as a novel treatment for depression.

The company's announcement highlighted ART12.11's ability to improve depression-related behaviors and reverse cognitive deficits associated with chronic stress. This positive preclinical data has generated significant investor interest, contributing to the stock's pre-market surge.

Artelo Biosciences' preclinical study compared ART12.11, a cocrystal combining cannabidiol and tetramethylpyrazine, to sertraline in male rats exposed to chronic stress over 28 days. The results showed that ART12.11 effectively restored key depression-related behaviors, suggesting its potential as a new therapeutic option for depression.